149 related articles for article (PubMed ID: 22111853)
1. Sipuleucel-T: a therapeutic cancer vaccine for the treatment of castration- or hormone-refractory prostate cancer.
Bulloch MN; Elayan MM; Renfroe HR
Expert Rev Clin Pharmacol; 2011 Nov; 4(6):685-92. PubMed ID: 22111853
[TBL] [Abstract][Full Text] [Related]
2. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
Sims RB
Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
[TBL] [Abstract][Full Text] [Related]
3. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.
Cheever MA; Higano CS
Clin Cancer Res; 2011 Jun; 17(11):3520-6. PubMed ID: 21471425
[TBL] [Abstract][Full Text] [Related]
4. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
Di Lorenzo G; Ferro M; Buonerba C
BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
[TBL] [Abstract][Full Text] [Related]
5. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.
Thara E; Dorff TB; Pinski JK; Quinn DI
Maturitas; 2011 Aug; 69(4):296-303. PubMed ID: 21621934
[TBL] [Abstract][Full Text] [Related]
6. Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial.
Antonarakis ES; Kibel AS; Yu EY; Karsh LI; Elfiky A; Shore ND; Vogelzang NJ; Corman JM; Millard FE; Maher JC; Chang NN; DeVries T; Sheikh NA; Drake CG;
Clin Cancer Res; 2017 May; 23(10):2451-2459. PubMed ID: 27836866
[No Abstract] [Full Text] [Related]
7. Prostate cancer vaccines.
Michael A; Relph K; Annels N; Pandha H
Expert Rev Vaccines; 2013 Mar; 12(3):253-62. PubMed ID: 23496665
[TBL] [Abstract][Full Text] [Related]
8. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
[TBL] [Abstract][Full Text] [Related]
9. Sipuleucel-T (APC8015) for prostate cancer.
So-Rosillo R; Small EJ
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1163-7. PubMed ID: 17020451
[TBL] [Abstract][Full Text] [Related]
10. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
Gardner TA; Elzey BD; Hahn NM
Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
[TBL] [Abstract][Full Text] [Related]
11. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
McKarney I
Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
[TBL] [Abstract][Full Text] [Related]
12. Sipuleucel-T: in metastatic castration-resistant prostate cancer.
Plosker GL
Drugs; 2011 Jan; 71(1):101-8. PubMed ID: 21175243
[TBL] [Abstract][Full Text] [Related]
13. An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer.
Wesley JD; Whitmore J; Trager J; Sheikh N
Hum Vaccin Immunother; 2012 Apr; 8(4):520-7. PubMed ID: 22370520
[TBL] [Abstract][Full Text] [Related]
14. Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.
GuhaThakurta D; Sheikh NA; Fan LQ; Kandadi H; Meagher TC; Hall SJ; Kantoff PW; Higano CS; Small EJ; Gardner TA; Bailey K; Vu T; DeVries T; Whitmore JB; Frohlich MW; Trager JB; Drake CG
Clin Cancer Res; 2015 Aug; 21(16):3619-30. PubMed ID: 25649018
[TBL] [Abstract][Full Text] [Related]
15. Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.
Paller CJ; Antonarakis ES
Hum Vaccin Immunother; 2012 Apr; 8(4):509-19. PubMed ID: 22336881
[TBL] [Abstract][Full Text] [Related]
16. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
Huber ML; Haynes L; Parker C; Iversen P
J Natl Cancer Inst; 2012 Feb; 104(4):273-9. PubMed ID: 22232132
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy: sipuleucel-T and beyond.
Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
[TBL] [Abstract][Full Text] [Related]
18. Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer.
Madan RA; Schwaab T; Gulley JL
J Natl Compr Canc Netw; 2012 Dec; 10(12):1505-12. PubMed ID: 23221788
[TBL] [Abstract][Full Text] [Related]
19. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.
Buonerba C; Ferro M; Di Lorenzo G
Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
Lü C; Williams AK; Chalasani V; Martínez CH; Chin J
Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
